ClinicalTrials.gg
CompletedNCT07146750Updated Apr 20, 2026

A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants

A Phase 1 interventional study of SAR445229 in Healthy Volunteers, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female participant, between 18 and 55 years of age, inclusive, at the time of signing the form (ICF).
  • Certified as healthy by a comprehensive clinical assessment [detailed medical history and complete physical examination including neurological exam (at screening and D1), skin, and mucous membranes].
  • Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, between 18.0 and 30.0 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Known history of significant or suspected current significant immunosuppression, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Any or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and cured for more than 5 years prior to baseline).
  • History of solid organ (including corneal transplant) or stem cell transplant.
  • Any pre-planned major elective surgery known about at baseline visit that in the Investigator's opinion would impede participation in the study.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation, any volume, within 2 months before inclusion.
  • Any nicotine use within 4 weeks before study inclusion. Regular smoking more than 5 cigarettes or equivalent in nicotine per week, unable to stop smoking or using nicotine for duration of the study.
  • If female, pregnancy (defined as positive beta human chorionic gonadotropin [β-HCG] blood test), breast feeding.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (actual)

Study arms

  • Active comparator
    Group 1

    Participants will receive a single dose of subcutaneous amlitelimab (dose A) to the abdomen delivered by prefilled syringe (PFS).

    Combination Product: SAR445229

  • Experimental
    Group 2

    Participants will receive a single dose subcutaneous amlitelimab (dose A) to the abdomen delivered by prefilled pen (PFP).

    Combination Product: SAR445229

  • Active comparator
    Group 3

    Participants will receive a single dose of subcutaneous amlitelimab (dose B) to the abdomen delivered by PFS.

    Combination Product: SAR445229

  • Experimental
    Group 4

    Participants will receive a single dose of subcutaneous amlitelimab (dose B) to the abdomen delivered by PFP.

    Combination Product: SAR445229

Interventions

  • Combination productSAR445229

    Single dose

    Also known as: Amlitelimab

06

What researchers measure

Primary outcomes

  1. PK parameter: Cmax

    Maximum serum concentration observed.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  2. Pharmacokinetic (PK) profile: AUC last

    Area under the serum concentration versus time curve calculated using the trapezoidal method from time zero to the real time.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  3. Pharmacokinetic (PK) profile: AUC

    Area under the serum concentration versus time curve extrapolated to infinity.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

Secondary outcomes

  1. PK parameter: Tmax

    Time to reach Cmax.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  2. PK parameter: t1/2z

    Terminal half-life associated with the terminal slope (λz) determined

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  3. PK parameter: CL/F

    Apparent total body clearance after a single subcutaneous administration of a drug from the serum.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  4. PK parameter: Vz/F

    Apparent volume of distribution during the terminal (λz) phase.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  5. Pharmacokinetic (PK) profile: AUCext

    Percentage of extrapolated part of AUC.

    Time frame: From Day 1 up to End of study (approximately 24 weeks)

  6. Percentage of participants who experienced TEAEs including ISRs, TESAEs, and/or TEAESIs

    TEAEs (Treatment-Emergent Adverse Events) including ISRs (local tolerability assessment), TESAEs (Treatment-Emergent Serious Adverse Events), and/or TEAESIs (Treatment Emergent Adverse Event of Special Interest).

    Time frame: Up to end of study (approximately 24 weeks)

  7. Percentage of participants with potentially clinically significant abnormalities

    Clinically significant abnormalities including Clinical laboratory evaluations, Vital signs, electrocardiogram (ECG).

    Time frame: Up to end of study (approximately 24 weeks)

  8. Visual analog scale score for pain with subcutaneous administration

    VAS (visual analog scale) is used to evaluate pain at the treatment injection site. In a range between 0 to 10 where 10 is the worst pain.

    Time frame: Day 1

  9. Incidence of participants with ADA (antidrug antibody) against amlitelimab.

    Time frame: Up to end of study (approximately 24 weeks)

07

Study locations

1 site
  • Clinical Pharmacology of Miami- Site Number : 8400001
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartActual
Aug 25, 2025
Primary completionActual
Apr 8, 2026
CompletionActual
Apr 8, 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146750
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 25, 2025
Primary completion
Apr 8, 2026
Completion
Apr 8, 2026
Last update
Apr 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion